Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

U.S. stocks slide in final trading day of 2022

Published 12/30/2022, 10:29 AM
Updated 12/30/2022, 10:30 AM
© Reuters

By Scott Kanowsky -- U.S. markets edged lower in the last session of 2022, as stocks looked set to slip to their worst year in almost a decade and a half.

The Dow Jones Industrial Average dropped 260 points, or 0.78%, to 32,960.53 as of 09:56 ET (14:57 GMT), while the S&P 500 fell 34 points, or 0.89%, to 3,815.20 and the tech-heavy NASDAQ Composite decreased by 115 points, or 1.10%, to 10,363.32.

Friday's trading will bring an end to a difficult year for stocks, which have been hit by several headwinds including persistently high inflation and aggressive Federal Reserve interest rate hikes. All three of the major indices are now on course for their biggest annual declines since 2008 - an event that would also break a three-year streak of annual gains.

The Dow has managed to eke out a marginally better performance than the other indices. It is on course to slide by just under 9% in 2022, while the S&P 500 is down nearly 20% over the past one-year period. The NASDAQ is lower by more than 33%, reflecting a recent period of sharp declines for technology stocks reeling from the increases in borrowing costs and supply chain woes.

The NASDAQ is also on pace for its fourth negative quarter in a row. However, the Dow and S&P 500 are on track to bring three straight quarters of declines to an end.

In individual equities, Southwest Airlines (NYSE:LUV) is one of the stand-out performers, jumping into the green following a statement from the U.S. Transportation Secretary Pete Buttigieg that said the Biden administration will hold the carrier "accountable" if it fails to fulfill commitments to customers for "controllable delays and cancellations." The airline expects to run a normal flight schedule Friday after thousands of cancellations this week.

Kala Pharmaceuticals (NASDAQ:KALA) also surged by more than 28% after the FDA accepted the company's application to develop a new drug that targets an eye disease known as “persistent corneal epithelial defect."

Meanwhile, shares in Futu Holdings Ltd (NASDAQ:FUTU) shed nearly a quarter of their value after China's securities regulator banned the online brokerage from opening new accounts with investors on the Chinese mainland. Officials claimed Tencent-backed Futu had unlawfully conducted cross-border securities businesses without regulatory consent.

The schedule for economic data was light on Friday, but is set to pick up slightly next week with the release of the most recent non-farm payrolls report on January 6. Financial markets will be closed on Monday to observe the New Year's Day holiday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.